Conference reports

Treatment is prevention: ARV treatment in HPTN-052 reduces transmission by at least 96%: single transmission in treatment arm occurred before viral suppression

1 August 2011. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.

Daily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2 study

1 August 2011. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.

Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP

1 August 2011. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.

Elvitegravir vs raltegravir: 48 week results in treatment-experienced patients

1 August 2011. Related: Conference reports, Antiretrovirals.

Dolutegravir: 48 week results from phase II study in treatment-naive patients

1 August 2011. Related: Conference reports, Antiretrovirals.

Lersivirine: 48 week results compared to efavirenz in phase 2 treatment-naive study

1 August 2011. Related: Conference reports, Antiretrovirals.

Maraviroc plus atazanavir/r without nukes versus standard of care: 48 week results

1 August 2011. Related: Conference reports, Antiretrovirals.

SPARTAC trial: treatment in primary infection for 48 weeks shows small delay in disease progression

1 August 2011. Related: Conference reports, Antiretrovirals.

Hearing loss not associated with HIV in MACS and WIHS cohorts

1 August 2011. Related: Conference reports, Side effects, Coinfections and complications.

Pharmacokinetics of darunavir and fosamprenavir in pregnancy

1 August 2011. Related: Conference reports, Pregnancy, PK and drug interactions.

Low birth weight and preterm delivery

1 August 2011. Related: Conference reports, Pregnancy.

Hormonal contraception and HIV transmission risk

1 August 2011. Related: Conference reports, Pregnancy.

No difference in AIDS-free survival in children starting ART with a CD4% between 15%–24% compared to deferring until less than 15% in the PREDICT trial

1 August 2011. Related: Conference reports, Paediatric care.

Paediatric antiretroviral pipeline: update on etravirine and maraviroc

1 August 2011. Related: Conference reports, Paediatric care.

Prematurity not associated with early mortality in infants on ART

1 August 2011. Related: Conference reports, Paediatric care.

More metabolic abnormalities in children receiving a PI compared to NNRTI in NEVEREST study

1 August 2011. Related: Conference reports, Paediatric care, Side effects.

Free online resource for treatment decisions without access to genotype resistance tests

1 August 2011. Related: Conference reports, Drug resistance.

17th Annual Conference of the British HIV Association (BHIVA) 6-8 April 2011, Bournemouth

1 August 2011. Related: Conference reports.

Treatment in seroconversion maintains HIV specific immune responses similar to long term slow progressors

1 August 2011. Related: Conference reports, Treatment strategies, Basic science and immunology.

18th Conference on Retroviruses and Opportunistic Infections (CROI) 27 February-–3 March 2011, Boston

1 August 2011. Related: Conference reports.

Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials

1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.

DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching

1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.

Lopinavir/r monotherapy used as second-line therapy in resource-limited settings

1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.

Treating children previously exposed to single dose nevirapine: update on IMPAACT P1060 and NEVEREST

1 August 2011. Related: Conference reports, Pregnancy, Paediatric care.

Lopinavir/ritonavir oral solution toxicity in neonates

1 August 2011. Related: Conference reports, Paediatric care, Side effects.

Paediatric antiretroviral pipeline: darunavir and raltegravir

1 August 2011. Related: Conference reports, Antiretrovirals, Paediatric care.

Pharmacokinetics of different rifabutin dosing strategies with lopinavir/ritonavir-based ART

1 August 2011. Related: Conference reports, PK and drug interactions, TB coinfection.

Initiation of ART during breastfeeding can induce multidrug resistance in infants

1 August 2011. Related: Conference reports, Pregnancy.

First Workshop on Nanomedicine for Infectious Diseases of Poverty, 27-31 March 2011, Magaliesberg, South Africa

10 May 2011. Related: Conference reports.

17th Annual Conference of the British HIV Association (BHIVA), 6-8 April 2011, Bournemouth

1 May 2011. Related: Conference reports.

Atazanavir in pregnancy: 155 cases in London clinics

1 May 2011. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.

Co-morbidity and late presentation – findings from an over 50s cohort

1 May 2011. Related: Conference reports.

Health outcomes for young adults with perinatally acquired HIV infection following transfer to adult services

1 May 2011. Related: Conference reports, Paediatric care.

The use of calcaneal stiffness index to screen for osteoporosis in HIV-infected individuals

1 May 2011. Related: Conference reports.

Frequency and characteristics of long-term non-progressors and HIV controllers in the Chelsea and Westminster cohort

1 May 2011. Related: Conference reports.

Cerebral function in perinatally HIV infected young people and HIV uninfected sibling controls

1 May 2011. Related: Conference reports.

An audit of HIV care provision for Immigration Removal Centre patients

1 May 2011. Related: Conference reports, Treatment access.

12th International Workshop on Clinical Pharmacology of HIV Therapy, 13–-15 April 2011, Miami

1 May 2011. Related: Conference reports.

Quad reduces levels of oral contraceptives

1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.

Elvitegravir/cobicistat and acid reducing agents

1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.

Lopinavir/r reduces levels of rifabutin

1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.

Cobicistat has little impact on CYP2D6 and CYP2B6

1 May 2011. Related: Conference reports, Antiretrovirals.

Atazanavir levels indicate need for higher dose during pregnancy

1 May 2011. Related: Conference reports, Antiretrovirals, Pregnancy.

Etravirine lowers levels of maraviroc given at 300 or 600 mg twice daily

1 May 2011. Related: Conference reports, Antiretrovirals.

Once-daily 150-mg maraviroc explored in people taking atazanavir/ritonavir

1 May 2011. Related: Conference reports, Antiretrovirals.

Lopinavir troughs lower in children on once-daily dose with efavirenz

1 May 2011. Related: Conference reports, Antiretrovirals, Paediatric care.

Dose optimisation: 50 mg ritonavir-boosting, 3TC dosing and raltegravir once-daily

1 May 2011. Related: Conference reports, Antiretrovirals, Treatment strategies.

46th European Association for the Study of the Liver (EASL), 30 March-3 April 2011, Berlin, Germany

1 May 2011. Related: Conference reports.

Rapid report: state of HCV policy, treatment, access

1 May 2011. Related: Conference reports, Antiretrovirals.

18th Conference on Retroviruses and Opportunistic Infections (CROI), 27 February–-3 March 2011, Boston

1 May 2011. Related: Conference reports.

When to start ART in patients co-infected with TB: results from two trials presented at CROI

1 May 2011. Related: Conference reports, Antiretrovirals, TB coinfection.

Inflammation and intervention: how does HIV cause AIDS and how does it cause disease despite ART

1 May 2011. Related: Conference reports, Antiretrovirals.

18th Conference on Retroviruses and Opportunistic Infections (CROI), 27 February-–3 March 2011, Boston

1 April 2011. Related: Conference reports.

New antiretrovirals: dolutegravir, entry inhibitor (BMS-663068) and tenofovir pro-drug (GS-7340)

1 April 2011. Related: Conference reports, Antiretrovirals.

Immune-based treatment increases HIV-resistant CD4 cells in phase 1 study

1 April 2011. Related: Conference reports, Antiretrovirals.

Antiretroviral prevention: oral PrEP, gels and treatment studies

1 April 2011. Related: Conference reports, Antiretrovirals.

Further efficacy analyses from the iPrEx study

1 April 2011. Related: Conference reports, Antiretrovirals.

Topical gels as PEP and PrEP: animal and human studies

1 April 2011. Related: Conference reports, Antiretrovirals.

Maternal risk following short course HAART

1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.

Pre-term delivery and HAART

1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.

HAART more effective than AZT monotherapy in the Botswana PMTCT programme

1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.

Lopinavir/r monotherapy for PMTCT

1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.

No evidence of increased risk of MTCT with sequential pregnancies in UK and Ireland

1 April 2011. Related: Conference reports, Pregnancy.

Recently infected women at the time of delivery have a higher rate of in-utero transmission in PEPI-Malawi

1 April 2011. Related: Conference reports, Pregnancy.

Reduced CCL22 concentrations in cervicovaginal secretions from pregnant women

1 April 2011. Related: Conference reports, Pregnancy.